Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997383 | 0.87 | CYP2A6 (0.51) | CYP2A6MAPTNOS1POLBGRIA1 | |
| SCHEMBL14301819 | 0.82 | PYGL (0.47) | MAPTPOLBHRH4ALDH1A1LMNA | |
| SCHEMBL28173938 | 0.79 | CYP19A1 (0.58) | CYP19A1MAPTNOS1POLBMAOB | |
| SCHEMBL27848309 | 0.79 | CYP19A1 (0.58) | CYP19A1MAPTNOS1POLBMAOB | |
| SCHEMBL1673078 | 0.79 | CYP19A1 (0.76) | CYP19A1MAPTNOS1POLBMAOB | |
| SCHEMBL28389620 | 0.77 | CYP19A1 (0.59) | CYP19A1MAPTNOS1POLBMAOB | |
| SCHEMBL5828903 | 0.76 | CYP19A1 (0.51) | CYP19A1MAPTNOS1POLBMAOB | |
| SCHEMBL5828902 | 0.76 | CYP19A1 (0.51) | CYP19A1MAPTNOS1POLBMAOB | |
| SCHEMBL30917347 | 0.76 | CYP19A1 (0.60) | CYP19A1CYP2A6MAPTNOS1POLB | |
| SCHEMBL10172985 | 0.76 | CYP19A1 (0.58) | CYP19A1MAPTNOS1POLBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115427404-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4139291-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115427404-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-102633778-B | Synthesis method of anti-AIDS medicine delavirdine | NANJING ACESYS PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-04-16 | — | — | CN | disclosed |
| CN-103342705-A | Method for synthesizing pyrrole [1,2-a ] quinoxaline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2013-10-09 | — | — | CN | disclosed |
| CN-103333171-A | Synthetic method of pyrrole [1,2-a ] quinoxaline derivative | NANJING UNIVERSITY OF TECHNOLOGY | 2013-10-02 | — | — | CN | disclosed |
| CN-102633778-A | Synthesis method of anti-AIDS medicine delavirdine | NANJING ACESYS PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-08-15 | — | — | CN | disclosed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
| US-5866589-A | Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0797576-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | CYP19A1 4650/4885CYP2A6 3412/4885MAPT 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.